Antitumoral efficacy by systemic delivery of heparin conjugated polyethylenimine-plasmid interleukin-15 complexes in murine models of lung metastasis

Cancer Science

Volumn 102, Issue 7, 2011, Pages 1403-1409

  Zhou, Xikun ^a   Li, Xiaolei ^a   Gou, Maling ^a   Qiu, Ji ^a   Li, Jing ^b   Yu, Chuanjiang ^a   Zhang, Yinbin ^a   Zhang, Nannan ^a   Teng, Xiu ^a   Chen, Zhongwen ^a   Luo, Can ^a   Wang, Zhen ^a   Liu, Xiao ^a   Shen, Guobo ^a   Yang, Li ^a   Qian, Zhiyong ^a   Wei, Yuquan ^a   Li, Jiong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPARIN; HEPARIN POLYETHYLENIMINE PLASMID INTERLEUKIN 15 COMPLEX; INTERLEUKIN 15; POLYETHYLENEIMINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; FEMALE; LUNG METASTASIS; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEPARIN; INTERFERON-GAMMA; INTERLEUKIN-15; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMIDS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959274656     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01956.x     Document Type: Article

References (38)

1. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005; 74: 711-38.
2. Geiger J, Aneja MK, Rudolph C. Vectors for pulmonary gene therapy. Int J Pharm 2010; 390: 84-8.
3. Rodrigo-Garzon M, Berraondo P, Ochoa L, Zulueta JJ, Gonzalez-Aseguinolaza G. Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis. Cancer Gene Ther 2010; 17: 20-7.
4. Zou YY, Tornos C, Qiu X, Lia M, Perez-Soler R. p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. Clin Cancer Res 2007; 13: 4900-8.
5. Poulain L, Ziller C, Muller CD et al. Ovarian carcinoma cells are effectively transfected by polyethylenimine (PEI) derivatives. Cancer Gene Ther 2000; 7: 644-52.
6. Gou M, Men K, Zhang J et al. Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. ACS Nano 2010; 26: 5573-84.
7. Grabstein KH, Eisenman J, Shanebeck K et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264: 965-8.
8. Gill N, Lauzon NM, Ashkar AA. The role of IL-15 signaling in the induction of innate antiviral responses. Curr Signal Transduct Ther 2007; 2: 180-5.
9. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999; 17: 19-49.
10. Cooper MA, Bush JE, Fehniger TA et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002; 100: 3633-8.
11. Nishimura H, Hiromatsu K, Kobayashi N et al. IL-15 is a novel growth factor for murine gamma delta T cells induced by Salmonella infection. J Immunol 1996; 156: 663-9.
12. Carson WE, Giri JG, Lindemann MJ et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL2 receptor. J Exp Med 1994; 180: 1395-403.
13. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. Il-15 has stimulatory activity for the induction of B-cell proliferation and differentiation. J Immunol 1995; 154: 483-90.
14. Ohteki T. Critical role for IL-15 in innate immunity. Curr Mol Med 2002; 2: 371-80.
15. Fehniger TA, Yu HX, Cooper MA, Suzuki K, Shah MH, Caligiuri MA. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J Immunol 2000; 164: 1643-7.
16. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32.
17. Davies E, Reid S, Medina MF, Lichty B, Ashkar AA. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. J Leukoc Biol 2010; 88: 529-36.
18. Hull GW, McCurdy MA, Nasu Y et al. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 2000; 6: 4101-9.
19. Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573-81.
20. Yiang GT, Harn HJ, Yu YL et al. Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice. J Biomed Sci 2009; 16: 47.
21. Yu YL, Wei CW, Chen YL, Chen MHC, Yiang GT. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression. Int J Oncol 2010; 36: 365-70.
22. Kaspar M, Trachisel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007; 67: 4940-8.
23. Gautam A, Waldrep JC, Densmore CL et al. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Ther 2002; 9: 353-7.
24. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13: 169-83.
25. Klebanoff CA, Finkelstein SE, Surman DR et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8(+) T Cells. Proc Natl Acad Sci USA 2004; 101: 1969-74.
26. Baer MR, Pixley LA, Schriber JR et al. Prolonged administration of low-dose interleukin-2 (IL2) to patients (PTS) with acute myeloid leukemia (AML) in remission (CR) expands natural killer (NK) cells without significant clinical toxicity. Blood 1998; 92: 614a-5a.
27. Munger W, Dejoy SQ, Jeyaseelan R et al. Studies evaluating the antitumor-activity and toxicity of interleukin-15, a new T-cell growth-factor - comparison with interleukin-2. Cell Immunol 1995; 165: 289-93.
28. Yoshimuta T. Gene therapy for murine lung cancer using an adenoviral vector expressing lnterleukin-15. Kurume Med J 2004; 51: 225-33.
29. Tasaki K, Yoshida Y, Miyauchi M et al. Transduction of murine colon carcinoma cells with interleukin-15 gene induces antitumor effects in immunocompetent and immunocompromised hosts. Cancer Gene Ther 2000; 7: 255-61.
30. Kishida T, Asada H, Itokawa Y et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 2003; 8: 552-8.
31. Yonenaga Y, Mori A, Fujimoto A et al. The administration of naked plasmid DNA into the liver induces antitumor innate immunity in a murine liver metastasis model. J Gene Med 2007; 9: 299-307.
32. Yockman JW, Kim WJ, Chang CW, Kim SW. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma. Gene Ther 2007; 14: 1399-405.
33. Ramesh R, Saeki T, Templeton NS et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 2001; 3: 337-50.
34. Deng WG, Kawashima H, Wu GL et al. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res 2007; 67: 709-17.
35. Branco MC, Schneider JP. Self-assembling materials for therapeutic delivery. Acta Biomater 2009; 5: 817-31.
36. Mosqueira VCF, Legrand P, Morgat JL et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res 2001; 18: 1411-9.
37. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005; 60: 247-66.
38. Di Carlo E, Comes A, Basso S et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 2000; 165: 3111-8.